BIND gains on Phase II NSCLC data

Bind Therapeutics gained $1.11 (14%) to $8.94 after publication of an abstract containing preliminary data from a Phase II trial of BIND-014 to treat non-small cell lung cancer (NSCLC). The compound had a 63% disease control rate among 8 stage III/IV NSCLC patients who tested positive for the K-Ras (KRAS) mutation, including 25% with a partial response and 38% with stable disease after at least 12 weeks.

The abstract was published in advance of BIND's Nov. 19 poster presentation at the European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. ...